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The role of metabolism-excitation coupling in insulin secretion has long been apparent, but in recent years, in
parallel with studies of human hyperinsulinism and diabetes, genetic manipulation of proteins involved in
glucose transport, metabolism, and excitability in mice has brought the central importance of this pathway
into sharp relief. We focus on these animal studies and how they provide important insights into not only
metabolic and electrical regulation of insulin secretion, but also downstream consequences of alterations
in this pathway and the etiology and treatment of insulin-secretion diseases in humans.Introduction: Human Diseases Highlight the Importance
of b Cell Metabolism-Excitation Coupling
The pathway from glucose entry into the b cell, through metabo-
lism to electrical signaling and intracellular [Ca2+] (Figure 1), is
critical in control of insulin secretion, and it is becoming
increasingly apparent that many of the relevant genes underlying
human diabetes and hyperinsulinism are found in this pathway.
Established steps in response to elevated blood glucose are
uptake through glucose transporters, conversion to glucose-6-
phosphate by glucokinase, and metabolism to generate ATP. A
rise in cytoplasmic [ATP]:[ADP] leads to ATP-sensitive potas-
sium (KATP) channel closure at the plasma membrane, which,
in turn, results in membrane depolarization, opening of
voltage-dependent Ca2+, and voltage-gated K+ channels (Dukes
and Philipson, 1996; Philipson, 1999; Rorsman and Trube, 1986;
Su et al., 2001). Calcium entry through Ca2+ channels results in
increased intracellular calcium concentration ([Ca2+]i), which, in
turn, triggers insulin exocytosis (Ashcroft and Rorsman, 1990;
MacDonald et al., 2005).
Congenital hyperinsulinism of infancy (HI), characterized by
constitutive insulin secretion despite low blood glucose (Ayns-
ley-Green, 1981), can result from abnormalities in several genes
involved inmetabolism-excitation (M-E) coupling, including loss-
of-function (LOF) mutations in the KATP channel and gain-of-
function (GOF) mutations in glucokinase (GCK), glutamate dehy-
drogenase, or short-chain acyl-CoA dehydrogenase (Palladino
et al., 2008). Conversely, permanent and transient neonatal dia-
betes mellitus (PNDM, TNDM) can result from LOF mutations in
glucokinase and GOF mutations in the b cell KATP channel
subunits (Smith et al., 2007). Maturity onset diabetes of the
young 2 (MODY-2) results from weaker LOF mutations in GCK
(Cuesta-Munoz et al., 2004; Gloyn, 2003a), and monogenic
diabetes caused by mitochondrial DNA mutation results from
defective b cell secretion (Maassen, 2002). Recent genome-
wide association studies (GWAS) identified multiple polymor-
phisms associated with type 2 diabetes (Cauchi et al., 2008;
Sladek et al., 2007; Unoki et al., 2008; Yasuda et al., 2008;
Zeggini et al., 2007), and again, many are in or near several
genes that encode for proteins involved in b cell M-E coupling442 Cell Metabolism 10, December 2, 2009 ª2009 Elsevier Inc.directly or indirectly via Ca-dependent processes. These include
CAPN10 (calpain10, an intracellular calcium-dependent cysteine
protease), SLC30A8 (a zinc transporter), KCNJ11 (the pore-
forming subunit of the KATP channel), and KCNQ1 (pore-forming
subunit of a voltage-gated K channel). Others, including
CDKAL1, HHEX, HNF4A, IGF2BP2, PPARG, and TCF7L2, are
potentially involved in b cell growth or proliferation and may indi-
rectly affect insulin secretion (Pascoe et al., 2008; Stancakova
et al., 2009).
During the last 10 years or so, while these genetic bases of
human disease have been identified, detailed knowledge of
in vivo b cell function has come from genetically modified
mice.We focus on how these studies, in dissectingM-E coupling
in vivo, inform islet function in the intact animal and the dysfunc-
tions that result in hyperinsulinism and diabetes. In many cases,
different gene products fulfill similar roles in human and mouse
b cells, and extrapolation from mouse to man is not automatic.
Nevertheless, emerging themes from mouse studies not only
provide mechanistic insights to the metabolic regulation of
insulin secretion and the downstream consequences of altered
genes, but in many cases may directly predict and inform the
etiology of the human diseases.
Mouse Models of Altered Glucose Uptake and Glucose
Metabolism
Loss of Membrane Glucose Transporters Causes
Diabetes
Although both GLUT1 and GLUT2 isoforms may be present in
human islets (Richardson et al., 2007), GLUT2 is themain isoform
expressed in rodent pancreatic b cells (Efrat et al., 1994; Tho-
rens, 2001). Inactivation of GLUT2 (GLUT2/) in mice leads to
severe hyperglycemia accompanied by high circulating fatty
acids, and GLUT2/mice die within the first 3 weeks after birth
(Guillam et al., 1997). Isolated islets show loss of first-phase and
reduced second-phase glucose-stimulated insulin secretion
(GSIS) (Guillam et al., 1997), reflecting a lack of glucose uptake
into the b cell. Re-expression of glucose transporters in GLUT2
knockout islets (using recombinant lentiviral expression or by
crossing with mice overexpressing GLUT2 or GLUT1 under Rip
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ReviewFigure 1. Schematic Illustration of the Glucose-Stimulated Insulin
Secretory Pathway in b Cells
(A) Hematoxylin and eosin-stained paraffin section of mouse pancreas. The
pancreas is composed of exocrine tissue and endocrine tissue (islet of Lang-
erhans). Islets contain different cell types, including the insulin-secreting
b cells. Arrows point to exocrine and endocrine tissue.
(B) Schematic illustration of the b cell glucose-stimulated insulin secretion
pathway. Glucose entering the b cell through glucose transporters (GLUT2)
is phosphorylated by glucokinase (GK) and metabolized by glycolysis (cyto-
plasm) and tricarboxylic acid (TCA) cycle (mitochondria). A rise in the [ATP]:
[ADP] ratio resulting from oxidative metabolism inhibits the ATP-sensitive K+
channels (KATP) at the cell surface, causing membrane depolarization and
opening of voltage-dependent Ca2+ channels (VDCC). This results in a rise
of intracellular [Ca2+], which stimulates insulin secretion. Voltage-dependent
outward K+ channels (Kv) are involved in membrane repolarization andcontrol) restores normal GSIS (Guillam et al., 2000; Thorens
et al., 2000).
Alterations in Glucokinase Activity Cause Diabetes
and Hyperinsulinism
Following entry into the b cell, glucose is phosphorylated byGCK
and then metabolized through glycolytic and oxidative pathways
(Matschinsky, 1996) (Figure 1B). In humans, GOF mutations in
either GCK or mitochondrial glutamate dehydrogenase (GDH)
cause HI, elevating [ATP]:[ADP] at any ambient glucose concen-
tration and suppressing KATP channel activity (Page et al., 1992;
Sakura et al., 1998). Reiterating key features, mice overexpress-
ing yeast hexokinase (Epstein et al., 1992a) or the GCK gene
itself (Shiota et al., 2001) are relatively hyperinsulinemic.
Conversely, homozygous inactivating GCK mutations cause
PNDM (Gloyn et al., 2002 ; Gloyn, 2003a; Njolstad et al., 2001).
Mice with deletion of the GCK gene in pancreatic b cells and
neurons, but not in the liver (by targeted disruption of the appro-
priate exon 1 variant), showed severe perinatal diabetes and
died shortly after birth (Grupe et al., 1995; Terauchi et al.,
1995). Confirming the critical role of b cell GCK, transgenic
re-expression only in b cells reversed diabetes in 50% of the
mice (Grupe et al., 1995).
Whereas homozygous LOF GCK mutations cause PNDM
(Gloyn, 2003a), heterozygous LOF mutations, resulting in only
partial reduction of GCK activity, underlie MODY-2 (Cuesta-
Munoz et al., 2004; Gloyn, 2003a), characterized by impaired
insulin secretion and diabetes onset in early adulthood, typically
not worsening over time (Fajans et al., 2001). Heterozygous b cell
GCK+/ mutant mice show glucose intolerance and impaired
GSIS (Bali et al., 1995; Grupe et al., 1995; Sakura et al., 1998),
but again, the diabetes does not progress, reiterating the
MODY-2 phenotype. Why the phenotype is nonprogressive
in humans and mice is interesting, given that the level of hyper-
glycemia that is reached (typically fasted blood glucose of
125–135mg/dl; Codner et al., 2006; Fajans et al., 2001; Sheha-
deh et al., 2005) is one that progresses to uncontrollable levels in
other forms of diabetes, including human type 2 (Guillausseau
et al., 2008; Matveyenko and Butler, 2008). Insulin levels are
typically normal, such that decreased insulin/glucose ratio
suggests increased insulin sensitivity in humans and mice
(Grupe et al., 1995; Katagiri et al., 1992; Terauchi et al., 1995).
Chronic (48–96 hr) exposure of GCK+/ islets to high glucose
concentration enhances glucose responsivity, whereas similar
exposure of wild-type islets induces dysfunction (Sreenan
et al., 1998). As we discuss below, an emerging idea from
cessation of insulin secretion. Factors that impair ATP production or down-
stream signaling are expected to suppress GSIS. Several genes that directly
or indirectly alter ATP production and therefore underlie a diabetic or hyperin-
sulinemic phenotype when mutated (humans and/or mouse models) are
shown in color: glucose transporter 2 (GLUT2), glucokinase (GK), nicotinamide
nucleotide transhydrogenase (Nnt), uncoupling protein 2 (UCP2), mitochon-
drial DNA mutations (mtDNA), and glutamate dehydrogenase (GDH). Muta-
tions that may indirectly affect channel activity are also shown.
(C) Schematic illustration of the electrical activity of b cells and the temporal
response to elevated glucose. In low (3 mM) glucose, the membrane is hyper-
polarized due to KATP activity, intracellular Ca ([Ca]) is low, and insulin is not
secreted. When glucose is elevated to stimulatory levels (11 mM), KATP chan-
nels close, and themembrane depolarizes due to L-type VDCC activity. Bursts
of APs, involving both VDCC and Kv channels, result in elevated [Ca], which, in
turn, triggers insulin secretion.Cell Metabolism 10, December 2, 2009 ª2009 Elsevier Inc. 443
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diseases may depend critically on the underlying cellular mech-
anisms. ‘‘Underexcited’’ islets, such as those with reduced
metabolic flux, may respond well to chronic restoration of excit-
ability, whereas ‘‘hyperstimulation’’ of otherwise normal islets
may be detrimental.
A first polygenic mouse model of noninsulin-dependent dia-
betes mellitus (Terauchi et al., 1997) was obtained by crossing
heterozygous GCK+/ mice (Terauchi et al., 1995) with homozy-
gous insulin receptor substrate 1 knockout (IRS-1/) mice.
Parental IRS-1/mice were insulin resistant but did not develop
diabetes due to compensatory b cell hyperplasia (Araki et al.,
1994; Tamemoto et al., 1994). Importantly, GCK+//IRS-1/
mice showed hyperglycemia despite b cell hyperplasia and
became overtly diabetic with age (Terauchi et al., 1997), experi-
mentally confirming that genetic combination of insulin resis-
tance and reduced insulin secretion can lead to diabetes.
Any consequences of GCK deficiency on electrical activity
should be absent in animals that lack glucose-regulated KATP
channels. Perinatal lethality was avoided in GCK//Kir6.2/
double knockout mice, although they were still insulin deficient
and still died prematurely (Remedi et al., 2005). However, hetero-
zygous GCK+/ animals, which were markedly diabetic on the
Kir6.2 wild-type background, became only mildly glucose intol-
erant on the Kir6.2/ background, essentially behaving like
Kir6.2/ mice (see below) (Remedi et al., 2005), confirming
that a major feature of GCK deficiency is indeed reduced excit-
ability via enhanced KATP channel activity.
Alteration of Mitochondrial Proteins Involved
in Regulation of ATP Production and Expenditure:
Indirect Action via Electrical Signaling
Mitochondria provide the major ATP-generating capacity of
b cells (Erecinska et al., 1992; Maechler and Wollheim, 2001).
Overactive mitochondrial metabolism will increase cytosolic
[ATP]:[ADP], leading to closure of b cell KATP channels and
enhancing secretion (see below) (Figure 1). Conversely, impaired
mitochondrial metabolism will decrease [ATP]:[ADP], preventing
KATP channel closure and suppressing secretion (Wallace, 2001).
Uncoupling proteins (UCPs) dissociate mitochondrial substrate
oxidation from ATP synthesis (Figure 1). UCP2 activation
contributes to decreased reactive oxygen species (ROS) forma-
tion and free fatty acid transport/metabolism but mostly reduces
the efficiency of ATP generation (Arsenijevic et al., 2000; Himms-
Hagen and Harper, 2001; Nishikawa et al., 2000; Samec et al.,
1998). UCP2 is present in b cells, and consistent with above
predictions, UCP2/ mice demonstrate increased circulating
insulin, without changes in peripheral insulin sensitivity (Joseph
et al., 2002; Zhang et al., 2001). UCP2/ islets show increased
[ATP] and hypersecretion of insulin at any glucose concentration
(Joseph et al., 2002; Zhang et al., 2001). When fed a high-fat diet,
these mice show improved b cell glucose sensitivity, enhanced
GSIS, and increased insulin content (Joseph et al., 2002).
Several animal models support the idea that UCP2 upregulation
and consequent inefficient ATP production is a feature of gluco-
lipotoxic conditions (Chan et al., 1999). Mice and rats fed a
high-fat diet show upregulation of UCP2 gene expression and
elevated plasma lipids (Briaud et al., 2002; Chan et al., 2001).
Fa/fa rats (leptin-receptor deficient) and ob/ob mice (leptin defi-
cient) are popular models of obesity-induced diabetes, and both444 Cell Metabolism 10, December 2, 2009 ª2009 Elsevier Inc.show upregulation of UCP2 mRNA in b cells (Kassis et al., 2000;
Zhang et al., 2001). Knockout of the UCP2 gene in the ob/ob
mouse background improved GSIS and reduced blood glucose
(Zhang et al., 2001).
In C57Bl6 mice, reported by some groups to exhibit impaired
insulin secretion relative to other strains (Toye et al., 2005),
mutations in the nicotinamide nucleotide transhydrogenase
(Nnt) have been identified. Nnt is a nuclear-encoded mitochon-
drial protein catalyzing reversible reduction of NADP+ by NADH
and promoting proton translocation across the membrane and
detoxification of ROS (Arkblad et al., 2005; Hoek and Rydstrom,
1988). Accumulation of ROS in the mitochondrial matrix can
increase UCP2 activity, enhancing proton leakage and impairing
ATP production (Echtay et al., 2002; Krauss et al., 2003). Nnt-
transgenic mice showed impaired glucose tolerance and loss
of both b cell ATP synthesis and GSIS, consistent with a direct
effect of impaired ATP production on KATP channel activity
(Freeman et al., 2006). No mutations in mitochondrial enzymes
have been reported in human diabetes, but a few mutations in
mitochondrial DNA (mtDNA) have. Mitochondria are a major
source of free radicals, as a result of electrons leaking into the
mitochondrial matrix reacting with molecular oxygen. An
A3243G mutation in the tRNA(Leu(UUR)) gene was identified
as a common diabetes-causing mitochondrial DNA mutation.
Mutation carriers exhibit reduced first- and second-phase insulin
secretion (Maassen et al., 2004), although the underlying molec-
ular mechanisms are unclear. A mouse model of mitochondrial
diabetes was generated by disruption of the nuclear gene
Tfam, a transcriptional activator essential for mtDNA expression
in b cells (Silva et al., 2000). These mice showed depletion of
mtDNA and developed diabetes at 5 weeks. Again, consistent
with impaired M-E coupling, dispersed b cells demonstrated
hyperpolarized mitochondria, impaired Ca2+ signaling, and
decreased GSIS. As in other models in which the primary defect
is in M-E coupling, older Tfam mutant mice showed reduced
b cell mass, indicating secondary progression (Silva et al.,
2000). Recently, a transgenic mouse expressing mutant mtDNA
polymerase g (D181A polyg) under insulin promoter control
was generated (Bensch et al., 2009) to cause accumulation
of mtDNA mutations in b cells. Despite males being overtly
diabetic and females being glucose intolerant by 6 weeks of
age, GSIS was normal in isolated islets, suggesting a non-islet
mechanism.
Oxygen-sensing pathways have also been implicated in
modulation of insulin secretion: both b cell-specific (bVhlKO)
and whole-pancreas (VhlKO) knockout of von Hippel-Lindau
(VHL) protein, which controls the degradation of hypoxia-induc-
ible factor (HIF), are glucose intolerant. Isolated islets show
altered expression of b cell glucose transporter and glycolytic
genes, impaired glucose uptake and metabolism, and reduced
GSIS (Cantley et al., 2009; Zehetner et al., 2008). Hif1a is
expressed in these b cells, and deletion of Hif1a restores
GSIS in these mice (Cantley et al., 2009; Zehetner et al.,
2008). b-cell-specific Vhl-deficient mice hypersecrete insulin
at low glucose concentration but have impaired GSIS and
increased [Ca2+]i (Cantley et al., 2009; Zehetner et al., 2008).
Thus, impaired mitochondrial oxidation and/or oxygen-sensing
mechanisms may all contribute to altered secretion via altered
M-E coupling.
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of Hyperinsulinism and Diabetes
KATP Knockout and Dominant-Negative Mice as Models
of Hyperinsulinemia
b cell KATP channels are complexes of the sulfonylurea receptor 1
(SUR1, ABCC8) and the potassium channel Kir6.2 (KCNJ11)
(Clement et al., 1997; Inagaki et al., 1995; Sakura et al., 1995;
Shyng and Nichols, 1997). In humans, LOF mutations in these
genes are major causes of HI (Aguilar-Bryan et al., 2001; Dunne
et al., 2004; Huopio et al., 2002a; Stanley, 2002). Reduction of
channel expression at the cell surface, loss of MgADP stimula-
tion, or abolished channel activity are primary defects (Dunne
et al., 1997; Nestorowicz et al., 1998; Nichols et al., 1996; Shyng
et al., 1998). Kir6.2/ and SUR1/ mice (Miki et al., 1998;
Seghers et al., 2000; Shiota et al., 2002), aswell asmice express-
ing a dominant-negative Kir6.2 mutant transgene in b cells
(Kir6.2[AAA] [Koster et al., 2002] or Kir6.2[G132S] [Miki et al.,
1997], both ofwhichdisrupt the selectivity filter) havebeengener-
ated. Kir6.2/ and SUR1/ mice (Miki et al., 1998; Seghers
et al., 2000; Shiota et al., 2002) lacking KATP in multiple tissues
and Kir6.2[G132S] mice that specifically lack b cell KATP (Miki
et al., 1997) show a complex and surprising phenotype that
does not trivially replicate human HI. These mice reportedly
demonstrate transient hyperinsulinemia and hypoglycemia as
neonates, but islets from adult SUR1/ or Kir6.2/ mice show
a dramatic loss of insulin secretion at all glucose concentrations,
and the animals are relatively hypoinsulinemic (Miki et al., 1998;
Seghers et al., 2000; Shiota et al., 2002). In Kir6.2[G132S] mice,
loss of b cell mass was reported (Miki et al., 1997), although
hyperglycemia was apparently spontaneously improved and
insulin content even increased in older mice (Oyama et al., 2006).
However, b-cell-specific Kir6.2[AAA] dominant-negative mice,
which lose KATP channel activity in only 70% of b cells, exhibit
elevated circulating insulin levels that persist through adulthood,
with essentially normal insulin content and islet morphology (Kos-
ter et al., 2002). Heterozygous Kir6.2+/ and SUR1+/ mice, with
60% reduction in KATP density in every cell, show a similar
phenotype (Remedi et al., 2006). Thus, whereas heterozygous
Kir6.2+/ and SUR1+/ mice, as well as Kir6.2[AAA] mice, all
show enhanced glucose tolerance and increased GSIS (Remedi
et al., 2006), Kir6.2/ and SUR/ mice (100% reduction in
KATPdensity) are glucose intolerant. Complete lackofKATPactivity
has been reported in b cells from some HI patients (Kane et al.,
1996), but the phenotype of many HI mutations would suggest
that KATP is unlikely to be completely absent (de Lonlay et al.,
2002; Huopio et al., 2002a, 2002b; Shyng et al., 1998), and active
KATP channels and diazoxide sensitivity have been detected in
some patients (Henwood et al., 2005; Lin et al., 2006). The prog-
ressof thediseasecanbecomplex, andalthoughsurgical removal
of excess pancreatic tissue may result in diabetes, it is also
observed that some nonsurgically treated patients spontaneously
cross over to diabetes (Grimberg et al., 2001;Huopio et al., 2002a;
Leibowitz et al., 1995). Apparent recapitulation of this complex
phenotype in mice with variable loss of KATP channels suggests
that a similar mechanism may be operating in mice and humans.
Overactive b Cell KATP Channel in Mice Causes Neonatal
Diabetes
GOF KATP channel mutations resulting in ‘‘overactive’’ b cell
channels are expected to decrease excitability and suppressGSIS. Mice expressing mutant KATP channels with reduced
ATP sensitivity only in pancreatic b cells (Kir6.2[DN2-30]) devel-
oped severe NDM and died within days of birth (Koster et al.,
2000), predicting the subsequent demonstration that GOFmuta-
tions in Kir6.2 (KCNJ11) and SUR1 (ABCC8) are common causes
of human TNDM and PNDM (Gloyn et al., 2004; Hattersley and
Ashcroft, 2005). These mutations reduce sensitivity to ATP
inhibition by decreasing the affinity of the ATP-binding pocket
for the nucleotide or by allosterically decreasing ATP affinity
(Ashcroft, 2006; Nichols, 2006). Recently, inducible KATP GOF
transgenic mice under Cre-recombinase control have been
generated (Girard et al., 2009; Remedi et al., 2009). Both rat
insulin promoter (Rip-Cre)- (Herrera, 2002) and tamoxifen-induc-
ible Pdx1PBCreERTM (Zhang et al., 2005) (Pdx-Cre)-driven
transgenes lead to severe glucose intolerance around weaning
(Rip-Cre) or within 2 weeks after tamoxifen injection (Pdx-Cre)
and progress to severe diabetes (Girard et al., 2009; Remedi
et al., 2009). They also show growth retardation and dramatic
reduction of insulin content accompanied by profound loss of
b cell mass over time (Remedi et al., 2009). Importantly, synge-
neic islet transplantation or chronic treatment with glibencla-
mide, initiated prior to tamoxifen induction, not only prevented
the development of diabetes, but also maintained both pancre-
atic islet architecture and b cell mass (Remedi et al., 2009).
Control-based genetic studies (Gloyn, 2003b), metanalysis
(Nielsen et al., 2003; Schwanstecher et al., 2002), and GWAS
(Saxena et al., 2007; Zeggini et al., 2007) have established the
E23K polymorphism in Kir6.2 as a risk factor in type 2 diabetes.
Although early studies failed to demonstrate a significant effect
of E23K on recombinant KATP channel properties (Riedel et al.,
2003; Sakura et al., 1996), subsequent studies reveal a small
rightward shift in ATP sensitivity (Schwanstecher et al., 2002;
Villareal et al., 2009). Such GOF behavior is predicted to
suppress GSIS, consistent with the findings in nondiabetic indi-
viduals who carry this polymorphism (Chistiakov et al., 2009;
Florez et al., 2004; Nielsen et al., 2003; Villareal et al., 2009). In
addition to severely diabetic transgenic mice (Koster et al.,
2000), additional KATP GOF (Kir6.2[DN2-30]) transgenic mouse
lines with lower levels of transgene expression exhibit normal
islet morphology and insulin content but are glucose intolerant
(and more so on high-fat diet) (Koster et al., 2006), reiterating
the general phenotype of humans carrying the E23K polymor-
phism (Villareal et al., 2009).
Mouse Models of Altered Ca Channels
The Role of L-Type High-Voltage-Activated Ca Channels
in Hyperinsulinemia and Diabetes
TheCav1 subfamily, comprising fourmembers (Cav1.1 toCav1.4)
(Hofmann et al., 1999), generates L-type voltage-dependent Ca
channels (VDCCs) involved in insulin secretion (Ichii et al., 2005;
Mears, 2004; Yang and Berggren, 2005a, 2005b). Cav1.2 and
Cav1.3 may be the dominant subunits (Barg et al., 2001;
Iwashima et al., 1993; Yang et al., 1999) (Figure 1). Cav1.3
/
mice are viable with no major disturbances in insulin secretion
even though they show deafness, bradycardia, and arrhythmias
(Platzer et al., 2000), suggesting that Cav1.3 is not normally
a major player in mouse b cell insulin secretion. Cav1.2
/ mice
die in utero before day 15, presumably because of lack of func-
tional VDCC in the heart (Seisenberger et al., 2000), obviatingCell Metabolism 10, December 2, 2009 ª2009 Elsevier Inc. 445
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/)
mice (deleted exons in one allele of Cav1.2 and ‘‘floxed’’ exons
in the other, using Cre/loxP recombination) exhibit decreased
VDCC and a marked reduction in insulin exocytosis in response
to initial membrane depolarization (first-phase) but unaffected
second-phase secretion (Schulla et al., 2003). The b cell Cav1.2
is sensitive to dihydropyridines (DHPs), and these drugs almost
abolish GSIS in b cell lines (Minami et al., 2002).Cav1.2
/ b cells
shownoDHP-sensitive VDCC, but glucose-induced [Ca2+]i oscil-
lations and action potential (AP) firing persist, suggesting that
L-type channels are necessary for insulin secretion, but not for
electrical activity and [Ca2+]i oscillations, perhaps indicating
compensatory overexpression of non-L-type channels in b cells
lacking Cav1.2 (Schulla et al., 2003). Timothy syndrome, due to
Cav1.2 overactivity, is characterized by deafness, webbing of
fingers and toes, congenital heart disease, and severe arrhyth-
mias and is associated with hypoglycemia (Splawski et al.,
2004), probably due to Cav1.2 overactivity in b cells. It seems
likely that LOF polymorphisms or mutations of L-type VDCC in
humans should be associated with diabetic syndromes, but
none have yet been identified, andwe speculate that this is again
because of compensatory upregulation of other subunits.
Non-L-Type High-Voltage-Activated Ca Channels
in the Regulation of Insulin Secretion
The role of non-L-type, high-voltage-activated Ca channels (e.g.,
Cav2.3 R-type Ca channel) in b cells is controversial, and some
studies indicate their absence in human islets (Braun et al.,
2008; Yang and Berggren, 2005b). But there is evidence for
association of Cav2.3 polymorphisms with impaired insulin
secretion and development of type 2 diabetes (Holmkvist et al.,
2007). They appear to play a role in second-phase insulin secre-
tion by mobilizing insulin reserve granules to the readily releas-
able pool in mice. Cav2.3 (CACNA1E) knockout (Cav2.3
/)
mice show impaired glucose tolerance and GSIS (Pereverzev
et al., 2002). In addition, genetic or pharmacological (using
R-type channel blocker SNX482) ablation of Cav2.3 channels
strongly suppresses second-phase secretion, but the first phase
is unaltered (Jing et al., 2005). Pancreatic cells from Cav2.3
/
mice show reduction of Ca2+ signaling and impairment of insulin
granule recruitment after the initial exocytotic burst (Jing et al.,
2005).
Voltage-Dependent Outward K+ Current: Repolarization
of b Cells and Insulin Secretion
Pancreatic b cells have prominent voltage-dependent outward
K+ (Kv) currents that mediate AP repolarization (Dukes and
Philipson, 1996; Philipson, 1999; Rorsman and Trube, 1986; Su
et al., 2001), and both Kv1 (KCNA) and Kv2 (KCNB) channel fami-
lies are involved (MacDonald et al., 2001) (Figure 1C). Kv2.1
expression is high in b cells (MacDonald et al., 2001; Roe
et al., 1996), and adenovirus-mediated expression of domi-
nant-negative Kv2.1 reduced (60%–70%) b cell delayed rectifier
currents and markedly enhanced GSIS (MacDonald et al., 2001).
Perfusion of mouse pancreas with Kv2.1 antagonists enhances
first- and second-phase insulin secretion but, as expected,
does not affect basal insulin levels (MacDonald et al., 2002). Phi-
lipson and colleagues (Philipson et al., 1994) generated Kv2.1-
overexpressing transgenic mice under Rip control. Although
expression levels were variable, themice showed hyperglycemia446 Cell Metabolism 10, December 2, 2009 ª2009 Elsevier Inc.and hypoinsulinemia, with normal b cell morphology and insulin
content (Philipson et al., 1994). Conversely, Kv2.1 knockout
(Kv2.1/) mice show reduced fasting blood glucose level and
elevated serum insulin (Jacobson et al., 2007), with enhanced
GSIS. Isolated Kv2.1/ b cells exhibit increased glucose-
induced AP duration, but firing frequency is diminished (Jacob-
son et al., 2007), consistent with loss of Kv currents and
enhanced Ca2+ entry during the AP, leading to increased insulin
secretion. SNARE proteins also affect insulin exocytosis (Daniel
et al., 1999). Syntaxin-1A (STX-1A) directly binds and regulates
Ca2+ channels (Yang et al., 1999), KATP (Kang et al., 2002), and
Kv2.1 channels in b cells (Leung et al., 2003, 2005). Transgenic
mice overexpressing STX-1A in b cells demonstrate fasting
hyperglycemia and reduced plasma insulin (Lam et al., 2005),
with reduced Cav currents but little change in the Kv and KATP
currents (Lam et al., 2005).
Multiple other K channels may be involved in insulin secretion
andmay ultimately be shown to be involved in secretion defects.
Variants in the voltage-gated potassium channel KCNQ1 gene
have recently been associated with susceptibility to type 2 dia-
betes, impaired fasting glucose, and b cell function in various
populations (Hu et al., 2009; Tan et al., 2009; Unoki et al., 2008;
Yasuda et al., 2008). KCNQ1/ mice demonstrate enhanced
insulin sensitivity and glucose tolerance, as well as decreased
fed and fasting glucose and insulin levels (Boini et al., 2009),
broadly consistent with a role in secretion, but the evidence for
KCNQ1 expression in islets is weak (Jonsson et al., 2009;Mussig
et al., 2009; Stancakova et al., 2009), and further investigation is
needed. The evidence that the KCNQ1 locus harbors control
elements that influence the imprinting of neighboring genes
(Lee et al., 1997; Smilinich et al., 1999), some associated with
type 2 diabetes, suggests that the mechanism responsible for
type 2 diabetes susceptibility may extend beyond the direct
effect of KCNQ1 (McCarthy, 2008). The role of Ca-activated
potassiumchannels in b cell function remains controversial. Early
studies demonstrated the presence of Ca2+-dependent K+
conductances in b cells (Atwater et al., 1983), and recent studies
haveargued for roles of small conductanceSKchannels in rodent
b cells (Tamarina et al., 2003); large conductance BK channels
may also be prominent in human b cells (Braun et al., 2008), but
again, more studies are clearly needed.
Genetic Alterations of Calmodulin in Hyperglycemia
and Neonatal Diabetes
Calmodulin and protein kinase C are two b cell calcium-binding
proteins with multiple potential roles in secretion (Hubinont
et al., 1984; Prentki andMatschinsky, 1987; Sugden et al., 1979).
Calmodulin may be a major calcium buffer, and transgenic mice
that overexpress calmodulin (CaM) specifically in pancreatic
b cells develop severe diabetes within hours after birth, demon-
stratingelevatedbloodglucoseandglucagon levelsandamarked
reduction in insulin levels (Epstein et al., 1992b), very much like
that seen in GOF Kir6.2 transgenic mice (Remedi et al., 2009). A
similar phenotype was found in transgenic mice overexpressing
inactive CaM-8 and containing a deletion of eight amino acids
in the central helix (Ribar et al., 1995), suggesting a mechanism
involving Ca2+ buffering rather than downstream calmodulin
signaling and consistent with Ca2+-sensitive pools of insulin
granules: vesicles colocalized with VDCC (Pertusa et al., 1999).
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M-E Coupling Leads to Ca2+: So What?
In a 2002 review, we systematically compared the phenotypic
consequences of transgenic manipulation of multiple genes in
pancreatic b cells (Nichols and Koster, 2002). Although genes
obviously involved in pancreatic development lead to loss of
b cells and inevitably insulin-dependent diabetes, many
signaling molecules have relatively mild consequences, except
for those involved directly in coupling glucose uptake, through
metabolism, to electrical signaling (e.g., GLUT2, GCK, Kir6.2,
SUR1). In these cases, even minor over- or underactivity leads
to under- or oversecretion and marked hyperinsulinism or dia-
betes. This is dramatic in the case of KATP, in which even rela-
tively small shifts in the ATP sensitivity lead to severe diabetes
(Girard et al., 2009; Koster et al., 2000; Remedi et al., 2009),
glucokinase knockout (Grupe et al., 1995; Terauchi et al.,
1995), or calmodulin overexpression (Epstein et al., 1992b; Ribar
et al., 1995). The data from human NDM patients are entirely
consistent: monogenic NDM is caused by loss of glucokinase
and by GOF mutations in KATP (Gloyn et al., 2004; Gloyn,
2003a). In the latter case, the more severe the ATP insensitivity,
the more severe the disease, but even mild shifts in ATP sensi-
tivity can cause neonatal disease (Hattersley and Ashcroft,
2005; Sivaprasadarao et al., 2007).
The reiteration of very similar phenotypes for mutations in
these genes seems quite telling: at least at early stages of life,
the pathway from glucose metabolism, initiated by glucokinase
activity, through excitability to elevated [Ca2+]i is critical and
cannot be compromised. The calmodulin-overactive mouse is
interesting in this regard. Early studies indicated that the primary
defect is probably the consequent increase in Ca2+ buffering,
leading to depressed [Ca2+]i, given that the phenotype is the
same when an inactive mutant is overexpressed (Easom, 1999;
Epstein et al., 1992b; Ribar et al., 1995), indicating that failure
of [Ca2+]i elevation is causal.
So what are the broader implications for b cell function and
diabetes? Sulfonylureas are effective treatments for NDM due
to KATP mutations (Hattersley and Ashcroft, 2005; Pearson
et al., 2006; Wambach et al., 2009), providing generally better
control of blood glucose than insulin and potentially without
the long-term failure found in type 2 patients (Rustenbeck,
2002). Total loss of mouse b cell GCK (i.e., a more severe defect
than likely present in most human LOFmutations; Njolstad et al.,
2001, 2003; Porter et al., 2005) results in failure to close KATP
channels (Sakura et al., 1998), and consequent diabetes is
at least partially abrogated by removal of KATP channels in
GK//Kir6.2/ double knockout mice (Remedi et al., 2005).
This suggests that GCK underactivity and potentially any other
defects upstream of KATP, i.e., between glucose uptake and
KATP closure, might be treatable at the level of the KATP channel,
and it is interesting that a recent report (Turkkahraman et al.,
2008) indeed suggests that such treatment may be effective in
GCK-dependent human NDM.
Secondary Consequences of Altered M-E Coupling
As discussed above, it is clear from studies of calmodulin over-
expressors (Epstein et al., 1992b; Ribar et al., 1995), GCK knock-
outs (Grupe et al., 1995; Terauchi et al., 1995), and KATP GOF
mice (Koster et al., 2000; Remedi et al., 2009) that diabetescan result simply from loss of insulin secretion due to failure of
M-E coupling. At the earliest stages of the disease (Koster
et al., 2000; Remedi et al., 2009) and chronically when protected
against the systemic consequences (Remedi et al., 2009), b cells
do not deteriorate and maintain normal insulin content even
though secretion in response to glucose remains refractory.
However, in the untreated situation, there is rapid deterioration:
b cell mass is lost, and insulin content disappears (Girard et al.,
2009; Koster et al., 2000; Remedi et al., 2009). These models,
therefore, provide important tools to understand the basis of
this secondary failure. There are many hypotheses behind the
‘‘glucotoxic’’ death of b cells in diabetes (Poitout and Robertson,
2008). It is clear that, in some animal models, it can result from
‘‘overstimulation’’ by glucose (Grill and Bjorklund, 2001) and,
because this can be protected against by infusion of diazoxide
(Guldstrand et al., 2002; Sako and Grill, 1990), implicitly involves
hyperactivation of Ca2+ stimulation. Grill and Bjorklund (2001)
examined long-term effects of diazoxide treatment on b cell
function in islets transplanted from normal rats into syngeneic
recipients previously made diabetic by streptozotocin (Hira-
matsu et al., 2000). After 8 weeks transplant, function was
improved, implying a protection against overstimulation and
consequent ‘‘Ca2+ toxicity’’ (which could lead to multiple path-
ways of cell death, including Ca-dependent proteases and
apoptosis). Such a mechanism may well occur in otherwise
normal islets facing an abnormal ‘‘glucose load,’’ but in the
case of reduced signaling through M-E coupling, this does not
seem possible, given that, even in late stages of disease, islets
remain refractory to stimulation and intracellular [Ca2+] remains
low (Girard et al., 2009; Remedi et al., 2009). Potential mecha-
nisms of ‘‘glucotoxicity’’ without Ca2+ toxicity are manifold,
including the generation of advanced glycosylation end products
(AGE) and other potentially toxic compounds (Del Prato et al.,
2007; Grill and Bjorklund, 2001; Zhao et al., 2009), and the islets
from these animals will, therefore, provide models for future
studies of the mechanisms of glucotoxic loss of b cells and
insulin content in the face of low intracellular [Ca2+].
M-E Coupling Leads to Ca2+: Surprises, Too
A clear picture emerging from animal models is that reducedM-E
coupling leads to reduced [Ca2+]i and reduced insulin secretion,
with remarkably small tolerance limits, and this is borne out in
humans by the finding that NDM results from relatively small
changes in ATP sensitivity of the KATP channel. But there are
surprises on the other side of the ‘‘see-saw.’’ The lack of hyper-
insulinism (in fact, relative hypoinsulinism) in mice completely
lacking KATP channels is not readily explained (Dufer et al.,
2004). Our studies have demonstrated that partial loss of KATP
has the expected effect of shifting secretion to lower glucose
levels, leading to enhanced glucose tolerance, but below
a certain level (<15% of normal KATP) (Nichols et al., 2007;
Remedi et al., 2006), there is crossover to marked undersecre-
tion due to downregulation of secretion itself in the face of a
maintained elevated [Ca2+]i. Although this might be ascribed
to some form of Ca2+ toxicity, it appears to be very labile and
readily reversible; the phenotype is closely replicated by chronic
pharmacological block of channel activity in mice implanted
with slow-release high-dose glibenclamide pellets, yet this
phenotype is completely reversed within hours of removal of
the drug (Remedi and Nichols, 2008). Again, such findings pointCell Metabolism 10, December 2, 2009 ª2009 Elsevier Inc. 447
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vance to humans. First, as discussed, there are reports that HI
patients with LOF KATP mutations can cross over to a glucose-
intolerant phenotype later in life, even without pancreatectomy
(de Lonlay et al., 2002; Dunne et al., 2004; Mazor-Aronovitch
et al., 2009). Second, chronic sulfonylurea treatment inevitably
fails in type 2 patients, again potentially involving chronic down-
regulation of secretion that can be reversed by b cell ‘‘rest’’
(Guldstrand et al., 2002; Pfutzner et al., 2006; Sargsyan et al.,
2008).
Concluding Remarks
Clearly, mice and humans are not genetically the same, and
differential islet morphology is a relevant issue. We do not
suggest that animal models can supplant clinical experience or
that the implications from animal models can automatically
translate to clinical relevance. However, many major players in
M-E coupling are likely to be the same in humans and mouse,
and recent studies show marked parallels in disease etiology
and progression resulting from their derangement in mouse and
man. Given the undisputed experimental advantages of the
mouse, both genetically and physiologically, mouse models
will continue to provide important avenues for explaining basic
mechanisms of M-E coupling, but also the molecular basis of
and therapeutic possibilities for treating diseases that result
from M-E coupling derangement.
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